<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               17 PATIENT COUNSELING INFORMATION<BR>               <BR>                  See FDA-approved patient labeling (Medication Guide)<BR>                  <BR>                     Hypersensitivity Reaction: Inform patients:<BR>                  <BR>                     that a Medication Guide and Warning Card summarizing the symptoms of the abacavir hypersensitivity reaction and other product information will be dispensed by the pharmacist with each new prescription and refill of EPZICOM, and encourage the patient to read the Medication Guide and Warning Card every time to obtain any new information that may be present about EPZICOM. (The complete text of the Medication Guide is reprinted at the end of this document.)<BR>                     to carry the Warning Card with them.<BR>                     how to identify a hypersensitivity reaction [see Warnings and Precautions (5.1), Medication Guide].<BR>                     that if they develop symptoms consistent with a hypersensitivity reaction they should call their doctor right away to determine if they should stop taking EPZICOM.<BR>                     that a hypersensitivity reaction can worsen and lead to hospitalization or death if EPZICOM is not immediately discontinued.<BR>                     that in one study, more severe hypersensitivity reactions were seen when ZIAGEN was dosed 600 mg once daily.<BR>                     to not restart EPZICOM or any other abacavir-containing product following a hypersensitivity reaction because more severe symptoms can occur within hours and may include life-threatening hypotension and death.<BR>                     that a hypersensitivity reaction is usually reversible if it is detected promptly and EPZICOM is stopped right away.<BR>                     that if they have interrupted EPZICOM for reasons other than symptoms of hypersensitivity (for example, those who have an interruption in drug supply), a serious or fatal hypersensitivity reaction may occur with reintroduction of abacavir.<BR>                     to not restart EPZICOM or any other abacavir-containing product without medical consultation and that restarting abacavir needs to be undertaken only if medical care can be readily accessed by the patient or others.<BR>                     EPZICOM should not be administered concomitantly with ATRIPLA, COMBIVIR, COMPLERA, EMTRIVA, EPIVIR, EPIVIR-HBV, TRIZIVIR, TRUVADA, or ZIAGEN.<BR>                  <BR>                  <BR>                      <BR>                     Lactic Acidosis/Hepatomegaly: Inform patients that some HIV medicines, including EPZICOM, can cause a rare, but serious condition called lactic acidosis with liver enlargement (hepatomegaly) [see Warnings and Precautions (5.2)].<BR>                  <BR>                  <BR>                     HIV-1/ HBV Co-infection: Patients co-infected with HIV-1 and HBV should be informed that deterioration of liver disease has occurred in some cases when treatment with lamivudine was discontinued. Patients should be advised to discuss any changes in regimen with their physician [see Warnings and Precautions (5.3)].<BR>                  <BR>                     HIV-1/HCV Co-Infection: Patients with HIV-1/HCV co-infection should be informed that hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected patients receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin [see Warnings and Precautions (5.4)].<BR>                  <BR>                     Redistribution/Accumulation of Body Fat: Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time [see Warnings and Precautions (5.6)].<BR>                  <BR>                     Information <BR>                     About<BR>                      HIV-1 Infection: EPZICOM is not a cure for HIV-1 infection and patients may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. Patients should remain under the care of a physician when using EPZICOM. <BR>                  Patients should be advised to avoid doing things that can spread HIV-1 infection to others.<BR>                  <BR>                     <BR>                        Do not share needles or other injection equipment.<BR>                     <BR>                     <BR>                        Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.<BR>                     <BR>                     <BR>                        Do not have any kind of sex without protection. Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood. <BR>                     <BR>                        Do not breastfeed. Lamivudine is excreted in human breast milk. It is not known if abacavir can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.<BR>                  <BR>                   Patients should be informed to take all HIV medications exactly as prescribed.<BR>                  COMBIVIR, EPIVIR, EPZICOM, TRIZIVIR, and ZIAGEN are registered trademarks of ViiV Healthcare.<BR>                  The other brands listed are trademarks of their respective owners and are not trademarks of ViiV Healthcare. The makers of these brands are not affiliated with and do not endorse ViiV Healthcare or its products.<BR>                  Manufactured for:<BR>                  ViiV Healthcare<BR>                  Research Triangle Park, NC 27709<BR>                  by:<BR>                  GlaxoSmithKline<BR>                  Research Triangle Park, NC 27709<BR>                  Lamivudine is manufactured under agreement from <BR>                  <BR>                     Shire Pharmaceuticals Group plc<BR>                  <BR>                  Basingstoke, UK<BR>                  ©2012, ViiV Healthcare. All rights reserved.<BR>                  EPZ:7PI<BR>               <BR>               <BR>            <BR>         </P></DIV></HTML>